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Abstract 24 
Borosilicate bioactive glasses (BBGs) have shown the capacity to promote a higher 25 
formation of new bone when compared to silicate bioactive glasses. Herein, we assessed 26 
the capacity of BBGs to induce the osteogenic differentiation of bone marrow 27 
mesenchymal stem cells (BM-MSCs), as a function of their substituted divalent cations 28 
(Mg2+, Ca2+, Sr2+). To this purpose, we synthesized BBG particles by melt quenching. 29 
The cell viability, proliferation and morphology, (i.e. PrestoBlue®, PicoGreen®, and 30 
DAPI and Phalloidin stainings, respectively) as well as protein expression (i.e. alkaline 31 
phosphatase, ALP, osteopontin, OP, and osteocalcin, OC) of BM-MSCs in contact with 32 
the BBGs were evaluated for 21 days. We observed an enhanced expression of the bone-33 
specific proteins (ALP, OP and OC) and high mineralization of BM-MSCs under BBG-34 
Mg and BBG–Sr conditioned osteogenic media for concentrations of 20 and 50 mg/ml 35 
with low cytotoxic effects. Moreover, BBG-Sr, at a concentration of 50 mg/ml, was able 36 
to increase the mineralization and expression of the same bone-specific proteins even 37 
under basal media conditions. These results indicated that the proposed BBGs improved 38 
the osteogenic differentiation of BM-MSCs. Therefore, showing their potential as 39 
relevant biomaterials for bone tissue regeneration, not only by bonding to bone tissue, but 40 
also by stimulating new bone formation. 41 
 42 
Key words: Borosilicate glasses, strontium, mineralization, osteogenic induction, BM-43 
MSCs 44 
  45 
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1. Introduction 46 
The properties of bioactive glasses (BGs) support their key relevance in clinical 47 
applications associated to bone tissue repair and regeneration. (1, 2) They are part of a 48 
tissue engineering-based strategy that can overcome the drawbacks of the traditionally 49 
used autologous bone grafts (e.g. lack of adequate amount and quality of bone, donor site 50 
morbidity). BGs are considered relevant for bone tissue repair since they: (i) promote 51 
osteointegration (forming a bone-like hydroxyapatite (HA) layer on their surface); (ii) are 52 
biocompatible; and (iii) their degradation shows positive biological effects after 53 
implantation. (2-5) There are, however, drawbacks associated with conventional BGs 54 
including in vitro cytotoxicity related to the release of Na+ ions, and interest in modified 55 
compositions has increased in recent years. (6) 56 
Recently, borosilicate bioactive glasses (BBGs) have attracted interest in bone tissue 57 
engineering. (1, 7, 8) BBGs have shown capability to improve the new bone formation 58 
when compared to silicate-based BGs. (9, 10) They present controllable degradation rates 59 
and have a high compositional flexibility that potentially allows BBGs to be tailored with 60 
enhanced osteogenic and angiogenic properties, as well as with antibacterial capacity. 61 
(11, 12) On one hand, as shown by Huang et al., a glass network composed of 62 
borosilicate’s have more controllable conversion rates to HA. (13) This has also been 63 
demonstrated to occur in vivo. (14) As a matter of fact, the addition of borate to the glass 64 
network can also be beneficial for bone healing, as well as formation, and maintenance 65 
of new bone, while supporting cell osteogenic differentiation. (15) Frequently, it has been 66 
associated with the increase in bone resistance to fracture. (16, 17) On the other hand, by 67 
exploiting the compositional flexibility of BBGs, inorganic divalent cations, such as 68 
Mg2+, Ca2+ and Sr2+ can be incorporated and play a key role in bone metabolism. For 69 
instance, Mg2+ increases bone formation rate, as well as stimulates bone cell adhesion 70 
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increasing their stability. (18, 19) The Ca2+ is known to be essential during the apatite 71 
formation process, being also favorable to osteoblast proliferation, differentiation and the 72 
mineralization of the extracellular matrix (ECM). (20) Sr2+ also has bone therapeutic 73 
potential. Different studies evidenced its beneficial effects on bone cells and bone 74 
formation in vivo, (21, 22) being even used for the treatment of osteoporosis. (23) 75 
In general BGs are known to be osteoinductive materials, capable of stimulating the 76 
function and osteogenic differentiation of bone and stem cells without any additional 77 
supplementation. Findings from Fu et al. suggested that the borosilicate 13-93B1 78 
scaffolds supported the proliferation and function of osteogenic Murine Osteocyte-like 79 
Cell Line MLO-A5,(15) while Gentleman et al. demonstrated that Sr2+-substituted BGs 80 
stimulated osteoblast metabolic activity promoting cell proliferation and ALP activity. 81 
(24) More significantly, Santocildes et al. demonstrated that Sr-containing BGs appeared 82 
to be capable of promoting osteoblastic differentiation in a proportion of bone marrow 83 
mesenchymal stem cells (BM-MSCs) that were in some way pre-committed to this 84 
lineage. (25) Liang et al. showed that borate glasses support the attachment and 85 
differentiation of human bone marrow derived mesenchymal stem cells and human 86 
mesenchymal stem cell derived osteoblasts. (26) 87 
The present study aims to fabricate three substituted BBGs to be used for bone tissue 88 
regeneration. We evaluated the impact of incorporating different divalent cations (i.e. 89 
Mg2+, Ca2+, Sr2+) into the BBGs on their ability to induce the BM-MSCs (known to 90 
differentiate into the mesodermal lineage cells, such as osteoblasts, osteoclasts and 91 
osteocytes (27)) to proliferate, differentiate and mineralize the ECM, while promoting 92 
bone formation. (11) 93 
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2. Experimental 94 
2.1. Preparation of BBGs 95 
The BBGs of general formula 0.05Na2O  xMgO  yCaO  (0.35-x-y)SrO  0.20B2O3  96 
0.40SiO2 (molar ratio, where x, y = 0.35 or 0.00, and x ≠ y) were synthesized by melt-97 
quenching. The suitable amounts of, silica (SiO2, Macherey-Nagel, Germany), boron 98 
oxide (B2O3, Alfa Aesar, Germany), sodium bicarbonate (NaHCO3, Sigma-Aldrich, 99 
Australia), and magnesium oxide (MgO, Sigma-Aldrich, Portugal), or calcium carbonate 100 
(CaCO3, Sigma-Aldrich, Portugal), or strontium carbonate (SrCO3, Sigma-Aldrich, 101 
Portugal) were thoroughly mixed with the addition of ethanol in a porcelain pestle with 102 
the help of a mortar, vacuum dried overnight and transferred to a platinum crucible. After 103 
entirely dried, each batch was heated to 1450 ˚C in air for 1 h and subsequently the melt 104 
was quickly poured into cold water to form the glass frit. Afterwards, the as-quenched 105 
glasses were ground in an Agate mortar (RETSCH, Germany) and sieved to a particle 106 
size <63 μm. Before the in vitro tests BBG-Mg (0.05Na2O  0.35MgO  0.20B2O3  107 
0.40SiO2), BBG-Ca (0.05Na2O  0.35CaO  0.20B2O3  0.40SiO2) or BBG-Sr (0.05Na2O 108 
 0.35SrO  0.20B2O3  0.40SiO2) were weighted, dried and sterilized at 160 ºC for at least 109 
2 h. 110 
2.2. Morphology and chemical composition of BBGs 111 
The morphology of the synthesized BBGs was observed by scanning electron microscopy 112 
(SEM, model S360, Leica Cambridge, UK) equipped with energy dispersive X-ray 113 
spectroscopy (SEM/EDS link-eXL-II) for the determination of the surface chemical 114 
composition. 115 
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2.3. Isolation and expansion of mesenchymal stem cells 116 
BM-MSCs were isolated from bone marrow of 4-5 week-old male Wistar rats according 117 
to the method established by Maniatopoulos et al. (28) and recently proposed by 118 
Santocildes et al. (25) BM-MSCs were expanded in basal medium consisting of 119 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, UK), supplemented with 120 
100 U/ml penicillin (Sigma,-Aldrich, UK) and 1 mg/ml streptomycin (Sigma-Aldrich, 121 
UK). Cells were cultured at 37 ºC in an atmosphere of 5% CO2. 122 
Prior to the in vitro studies, BM-MSCs, at passage 2, were harvested and seeded into 24 123 
well plates, at a density of 2×104 cells per well. Cells were cultured in the presence of the 124 
BBGs at concentrations of 20 and 50 mg/ml, for 7, 14 and 21 days under static conditions. 125 
The BM-MSCs cultured in the absence of BBGs were used as negative control and in the 126 
presence of 45S5 bioglass® as positive control. The BBGs at the desired concentrations 127 
and 45S5 bioglass® were deposited on top of the cells, in cell culture inserts with porous 128 
membranes (0.4 µm ThinCerts™ Cell Culture Inserts; Greiner, Germany), as used in 129 
previous works. (29) The ThinCerts™ were used as an inert platform to support the glass 130 
particles under cell culture conditions. All BBG compositions and controls were cultured 131 
in basal and osteogenic differentiation media (basal medium supplemented with 50 µg/ml 132 
ascorbic acid, 10 mM β-glycerophosphate and 10-8 M dexamethasone). Figure 1 presents 133 
a schematic of the experimental design. 134 
Figure 1. Schematic of the experimental design. 135 
2.4. Potential cytotoxic effect of BBGs dissolution on BM-MSCs 136 
Cell viability and proliferation (PrestoBlue® and PicoGreen® assays). The 137 
PrestoBlue® reagent (Fisher Scientific, UK) is a resazurin-based solution that is reduced 138 
to resorufin by viable cells which can be detected fluorimetrically. The cell viability assay 139 
7 
 
 7 
was executed according to the manufacturer’s instructions. In brief, the PrestoBlue® 140 
reagent was added to a final concentration of 10% to the wells and the cells were 141 
incubated for 1 h at 37 oC. Afterwards, 200 µl samples of the culture medium were 142 
removed and placed in 96-well plates and the resorufin fluorescence was quantified 143 
spectrophotometrically using a plate reader (Tecan Infinite M200). The fluorescence was 144 
determined at an excitation wavelength of 560 nm and emission wavelength of 590 nm. 145 
The metabolic activity was presented in fluorescence values and compared with the 146 
control (cell cultured in the absence of glass particles under basal medium conditions). 147 
The PicoGreen® dsDNA reagent (Invitrogen, USA) is an ultrasensitive fluorescent 148 
nucleic acid dye for quantification of double-stranded DNA (dsDNA) in solution. This 149 
assay enables the measurement of cell proliferation. After each culturing period, the cell 150 
monolayers were washed with PBS and then incubated at 37 ºC for 3 h followed by a 151 
freezing step at -80 ºC for at least overnight in ultra-pure water (1 ml) to ensure cell lysis. 152 
The assay was performed according to the manufacturer’s protocol. And the fluorescence 153 
was determined at an excitation wavelength of 485 nm and emission wavelength of 528 154 
nm. The DNA concentration was presented in µg/ml and compared with the control (cell 155 
cultured in the absence of glass particles under basal medium conditions). 156 
Cell morphology and distribution. After each culturing period the cell grown in tissue 157 
culture coverslips were washed with PBS and fixed with 4% formalin solution (0.5 ml) 158 
for 15 min at room temperature (RT). The cell layers were then washed with PBS, 159 
containing 0.2% Triton X, for 2 min. After the fixation and permeation steps, the cell 160 
monolayers were washed again with PBS and stained with 4,6-diamidino-2-phenyindole 161 
dilactate (1:1000 DAPI, Sigma, UK) for 2 min at RT, and phalloidin-162 
tetramethylrhodamine B isothiocyanate (Sigma, UK) for 1 h at RT. Finally, the cells were 163 
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washed and observed using an Axioplan 2 imaging fluorescent microscope with a digital 164 
camera QIC AM 12-bit (Zeiss, UK). 165 
2.5. Osteogenic capacity of BBGs on BM-MSCs 166 
Alkaline phosphatase quantification. The concentration of alkaline phosphatase (ALP) 167 
was determined for all the culture time periods, using the lysates used for DNA 168 
quantification. Briefly, the ALP quantity was assessed using the Alkaline Phosphatase, 169 
Diethanolamine Detection kit (Sigma-Aldrich, UK) in which p-nitrophenyl phosphatase 170 
(pNPP) solution is hydrolyzed by ALP to yellow free p-nitrophenol. In brief, a buffered 171 
pNPP solution was prepared and equilibrated at 37 ºC. Afterwards, 2% (v/v) of sample or 172 
control were added. Immediately after mixing the absorbance was read at 405 nm in a 173 
plate reader (Tecan Infinite M200) for ≈ 5 min. An ALP standard solution was used as 174 
control and buffer as blank. The units were calculated according to the following 175 
equation: 
(∆𝑨𝟒𝟎𝟓𝒏𝒎/ 𝐦𝐢𝐧  𝑻𝒆𝒔𝒕−∆𝑨𝟒𝟎𝟓𝒏𝒎/ 𝐦𝐢𝐧 𝑩𝒍𝒂𝒏𝒌)×𝒅𝒇×𝑽𝑭
𝟏𝟖.𝟓×𝑽𝑬
. Where df = dilution factor; VF = 176 
Volume of final solution; 18.5 = millimolar extinction coefficient of pNPP at 405 nm and 177 
VE = Volume of samples/ALP standard solution. ALP activity was calculated by 178 
normalizing ALP concentration per DNA concentration for each condition and time point. 179 
Alizarin red staining. After 21 days of culture, the cells grown in tissue culture 180 
coverslips were fixed in 70% ice-cold methanol at -20 °C at least for 30 min. The cell 181 
layers were then washed with PBS and dried overnight. Afterwards, cells were stained 182 
with alizarin red solution [342 mg of alizarin red, (Sigma-Aldrich, UK) in 25 ml of 183 
distilled water and the pH was adjusted to 4.1 with 10% ammonium hydroxide (Sigma-184 
Aldrich, UK)] for 10 min. Afterwards, the coverslips were washed with distilled water, 185 
dehydrated in an acetone/xylene (Sigma-Aldrich, UK) mixture and mounted using an 186 
aqueous mountant. The stained constructs were observed under an optical microscope 187 
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(BX51, Olympus Corporation, UK) and images were captured by a digital camera (DP70, 188 
Olympus Corporation, UK). The BM-MSCs morphology and mineral deposition was also 189 
observed using SEM (model S360, Leica Cambridge, UK) equipped with energy 190 
dispersive X-ray spectroscopy (SEM/EDS link-eXL-II) for the determination of the 191 
surface chemical composition. 192 
Immunodetection of bone-specific proteins. Osteopontin (OP) and osteocalcin (OC) 193 
protein expression of BM-MSCs was assessed by immunoassay technique to evaluate 194 
their osteoblastic differentiation. The procedures were executed according to the 195 
manufacturer’s instructions. The concentrations of OP and OC were determined for all 196 
the culture time periods, using the lysates used for DNA quantification. The OP 197 
quantitative determination was performed using Mouse/Rat Osteopontin Quantikine 198 
ELISA Kit (R&D Systems, UK). In brief, 50 µl of assay diluent RD1W and 50 µl of 199 
standard (2500 to 39 pg/ml), control and samples were added and the plate incubated for 200 
2 h at RT. After 4 washing steps and perfectly dried, 100 µl of Mouse/Rat OP Conjugated 201 
were added and incubated for 2 h at RT. The sandwich complex was washed 4 times and 202 
allowed to react with 100 µl of substrate solution before adding 100 µl of stop solution. 203 
Finally, the optical density was determined at 450 nm and the concentration of OP 204 
obtained from a standard curve plot. OC quantitative determination was performed by the 205 
use of Rat Gla-Osteocalcin High Sensitive EIA kit (Takara Clontech, Japan). In brief, 100 206 
µl of samples and standard solution (16 to 0.25 ng/ml) were incubated for 1 h at 37 ºC 207 
with the capture-antibody, rat osteocalcin C-terminus-specific antibody. After OC capture 208 
and 3 washing steps, 100 µl of the enzyme-labelled antibody (GlaOC4-30) specific to 209 
Gla-OC was incubated for 1 h at RT. The sandwich complex was washed 4 times and 210 
allowed to react with 100 µl of substrate solution for 10-15 min. Finally, after adding the 211 
stop solution the optical density was determined at 450 nm and the concentration of OC 212 
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obtained from a standard curve plot. OP and OC content was calculated by normalizing 213 
OP or OC concentration per DNA concentration for each condition and time point. 214 
2.6. Statistical analysis 215 
Results are expressed as mean ± standard deviation with n = 3 for each sample. Error bars 216 
represent standard deviations. The data was analyzed by non-parametric statistics: 217 
Kruskal-Wallis test (p<0.0001), followed by a Dunn’s Multiple Comparison test. *** 218 
p<0.001; ** p<0.01; * p<0.05 in respect to the control. 219 
3. Results and discussion 220 
3.1 Morphology of BBGs and their chemical composition 221 
BBGs’ frits were successfully obtained by melt quenching and ground in a controlled 222 
manner. Figure 2a, 2b and 2c show the SEM/EDS analysis of BBGs, which exhibited an 223 
angular shape with low sphericity and confirmed the successful incorporation of the 224 
different modifier divalent cations (i.e. Mg2+, Ca2+ and Sr2+). The composition of BBGs 225 
was confirmed in a prior work by the use of X-ray fluorescence and follows the general 226 
formula 0.05Na2OxMgOyCaO(0.35-x-y)SrO0.20B2O30.40SiO2 (molar ratio, where x, 227 
y = 0.35 or 0.00, and x ≠ y). (30) Moreover, studies after immersion in SBF, showed that 228 
the studied BBGs are bioactive due to the formation of bone-like apatite structures onto 229 
their surface, and the constant release of ions to the reaction media over time. (29) 230 
 231 
Figure 2. SEM/EDS micrographs of BBGs, a) BBG-Mg, b) BBG-Ca and c) BBG-Sr. 232 
SEM images are shown as insets, displaying the morphology of the glass particles. The 233 
specific modifier divalent cation is highlighted in yellow for each BBG. 234 
11 
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3.2 In Vitro biological evaluation 235 
Osteoblast differentiation can be divided into three stages: cell proliferation, ECM 236 
synthesis and maturation, and ECM mineralization, each with a cellular characteristic 237 
behavior. (31) 238 
3.2.1 Potential cytotoxic effect of BBGs leachables on BM-MSCs 239 
The effect of BBGs’ concentration on cell viability and proliferation was studied on a 240 
previous work. (29, 30) It showed that a concentration between 20 and 50 mg/ml did not 241 
significantly affect cell viability and proliferation. On the other hand, Romero et al. (32) 242 
studied the osteogenic response of BM-MSCs to strontium-substituted bioactive glasses 243 
(SrBG) and observed that 20 mg of Sr50BG promoted the osteoblastic differentiation of 244 
BM-MSCs. Based on these results, we decided to use BBGs concentrations of 20 and 50 245 
mg/ml. 246 
Herein, we cultured BM-MSCs in basal and osteogenic differentiation media for 7, 14 247 
and 21 days under static conditions, in the presence and absence of BBGs, in order to 248 
evaluate their biological activity. The cellular metabolism and proliferation was evaluated 249 
by quantifying the conversion of resazurin to resorufin by viable cells and the amount of 250 
double stranded DNA (live cells) in the culture wells; as well as their morphology. 251 
Fluorescence microscopy images showed the morphology of BM-MSCs in culture 252 
containing BBGs or 45S5 bioglass® (Figure 3). The adhered BM-MSCs exhibited a well-253 
spread morphology, exhibiting cell-to-cell contacts in a comparable manner on the BBGs 254 
conditioned cultures as in the control experiment. While BM-MSCs cultured with 45S5 255 
bioglass® presented a round shape for the last time point (21 days), suggesting cell death. 256 
At the same timepoint, especially for cultures under osteogenic differentiation media (e.g. 257 
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BBG-Sr), there was distinguishable well-spread polygonal shape cells, suggesting 258 
osteoblast-like morphology. 259 
 260 
Figure 3. BM-MSCs morphology observed by fluorescence microscopy, after 7, 14 and 261 
21 days culture with BBGs either under basal or osteogenic culture medium. Each sample 262 
was incubated at two different concentrations (20 and 50 mg/ml). Cells cultured with 263 
basal and osteo medium were used as negative control and 45S5 bioglass® incubated with 264 
medium was used as positive control. Nuclei stained blue by DAPI; Actin stained green 265 
by Phalloidin. 266 
 267 
Figure 4. Metabolic activity (PrestoBlue® assay) and proliferation (PicoGreen® assay) of 268 
BM-MSCs cultured either in basal or osteogenic media in the presence of different 269 
concentrations (20 and 50 mg/ml) of BBG-Mg (a, b), BBG-Ca (c, d) and BBG-Sr (e, f). 270 
The 45S5 bioglass® (g, h) was used as control. Standard culture medium was used as 271 
negative control. Results are expressed as mean ± standard deviation with n = 3 for each 272 
bar. The data was analyzed by non-parametric statistics: Kruskal-Wallis test (p<0.0001), 273 
followed by a Dunn’s Multiple Comparison test. *** p<0.001; ** p<0.01; * p<0.05 in 274 
respect to the control, i.e. BM-MSCs culture in basal media for the respective day of 275 
culture (i.e. 7, 14 and 21 days). 276 
 277 
From the PrestoBlue® data (Figure 4a, 4c, 4e and 4g) it is possible to observe that the 278 
metabolic activity of BM-MSCs increased over the 21 days of culture. In the first 7 days 279 
of culture, the BM-MSCs under conditioned cultures presented reduced viability in 280 
respect to the cells culture under basal condition (negative control), especially for BBG-281 
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Ca culture conditions, which may be due to the initial burst release of ions to the media. 282 
In contrast, from day 14, BM-MSC cultures under osteogenic media displayed a reduction 283 
of metabolic activity with respect to the control (absence of glass particles and cell 284 
cultured under basal medium). It is noteworthy that BM-MSC cultures at day 21 with 285 
45S5 bioglass® under osteogenic media showed very low metabolic activity when 286 
compared with the control experiment (osteogenic media), being consistent with the cell 287 
death observed by fluorescent microscopy (Figure 3). Complementary to the viability 288 
analysis, the cellular proliferation was also assessed by measuring the total cell DNA 289 
(Figure 4b, 4d, 4f, 4h). The PicoGreen® data showed an increase on the number of BM-290 
MSCs over time. However, under osteogenic media, the cells presented lower 291 
proliferation rates than cultures under basal media from day 14. Noteworthy, is the 292 
prominent reduction of BM-MSCs for cultures with BBG-Mg (osteogenic and basal 293 
media) and 45S5 bioglass® (osteogenic media) at day 21. To emphasize, BBG-Sr and 294 
45S5 bioglass® under osteogenic media showed a significant reduction on the cell 295 
proliferation at day 14 when compared with the cells cultured under basal media, 296 
suggesting an alteration of biological behavior. (33) Regarding the effect of 297 
concentration, there was no potential toxic effects with time except in the case of BM-298 
MSCs cultured in the presence of BBG-Mg (osteogenic and basal media) and 45S5 299 
bioglass® (osteogenic media) at day 21, where a large reduction in cell number was 300 
observed in relation to the control (basal media). 301 
3.2.2 Alkaline phosphate quantification 302 
It is commonly accepted that ALP is a key player in the process of osteogenesis, being 303 
ALP known to be involved in early stages of normal and pathological calcification. (34-304 
36) In general, an increase of the ALP activity is correlated with osteogenesis, increasing 305 
during the bone formation stage. (37) Not surprisingly, the ALP quantification data 306 
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(Figure 5) showed a significantly higher ALP activity when cells were cultured under 307 
osteogenic media rather than basal media. (38) However, at day 21 the levels of ALP 308 
activity on BBG-Mg, -Sr and 45S5 bioglass® cultured under osteogenic media are 309 
significantly higher than the cultures without glass addition (e.g. at day 21, under 310 
osteogenic media, the addition of 20 mg of BBG-Sr (c) induced a highly significant 311 
(p<0.001) enhanced ALP activity in relation to the cells cultured in the absence of glass 312 
particles). BBG-Mg, -Sr and 45S5 bioglass® were not capable of inducing the ALP 313 
protein expression alone, however, they were capable to increase the ALP expression 314 
during the differentiation process of BM-MSCs into osteoblasts under osteogenic media 315 
(for 21 days of cell culture). It is relevant to point out that previous studies quantified the 316 
chemical species released from BBGs in solution, demonstrating a higher concentration 317 
of Mg2+ and Sr2+ ions (2-fold) when compared with Ca2+ (from BBG-Mg, BBGs-Sr and 318 
BBG-Ca, respectively). (29, 30) The presence of higher concentration of specific ions 319 
(i.e. Mg2+ and Sr2+) might facilitate cell differentiation. It is also relevant to highlight the 320 
fact that along with the increase of ALP activity for the case of BBG-Mg and -Sr glasses 321 
there was observed an increase of cell proliferation. In contrast, the viability and 322 
proliferation data, presented a reduction of viable and live cells for the BM-MSCs 323 
cultured in the presence of these BBG-Ca and 45S5 bioglass®. Remarkably, BBG-Sr 324 
promoted the increase of ALP activity for both concentrations of glass particles, i.e. 20 325 
and 50 mg/ml. 326 
 327 
Figure 5. ALP activity of BM-MSCs (cultured either in basal or osteogenic media) in the 328 
presence of different concentrations (0, 20 and 50 mg/ml) of BBG-Mg (a), BBG-Ca (b) 329 
and BBG-Sr (c). The 45S5 bioglass® (d) was used as control. Results are expressed as 330 
mean ± standard deviation with n = 3 for each bar. The data was analyzed by non-331 
15 
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parametric statistics: Kruskal-Wallis test (p<0.0001), followed by a Dunn’s Multiple 332 
Comparison test. *** p<0.001; ** p<0.01; * p<0.05 in respect to the control, i.e. BM-MSCs 333 
culture in basal media for the respective day of culture (i.e. 7, 14 and 21 days). 334 
 335 
3.2.3 Matrix mineralization 336 
Similar results were found at day 21 after alizarin red staining for mineral deposits (Figure 337 
6). In agreement with ALP activity data, cells cultured under osteogenic media yielded 338 
more bone-like nodules (intense red spots dispersed in the cell culture), resulting from 339 
ECM mineralization. (35) Of importance, and corroborating with ALP activity data, 340 
mineral deposits were more evident with BBG-Mg, -Sr and 45S5 bioglass® (Figure 6a, 341 
6c and 6d) and an increase of red nodules with the increase of concentrations can be 342 
observed in the case of the cells cultured in the presence of BBG-Sr (Figure 6c, osteo 20 343 
mg/ml and 50 mg/ml). Higher concentrations of BBG-Sr and 45S5 bioglass® show the 344 
presence of red nodules even in cells cultured in basal medium. However, ALP activity 345 
data, suggests that BBG-Sr and 45S5 bioglass® (Figure 6c and 6d basal for a concentration 346 
of 50 mg/ml) are capable to induce ECM mineralization by themselves. Therefore, the 347 
combination of ALP activity and mineralization results suggest the use of BBG-Sr to 348 
promote osteogenesis. (39) 349 
 350 
Figure 6. Alizarin red staining of BM-MSCs cultured during 21 days, either in basal or 351 
osteogenic media in the presence of different concentrations (20 and 50 mg/ml) of BBG-352 
Mg (a), BBG-Ca (b) and BBG-Sr (c). The 45S5 bioglass® (d) was used as control. 353 
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 354 
Figure 7. SEM micrographs of BM-MSCs in the presence of different concentrations (20 355 
and 50 mg/ml) of BBG-Mg (a), BBG-Ca (b) and BBG-Sr (c) after 21 days of cell culture 356 
either in basal or osteogenic media. Higher SEM magnifications are shown as insets, 357 
highlighting the formed apatite-like structures. The 45S5 bioglass® was used as a control. 358 
In Figure 7 we presented SEM micrographs of BM-MSCs cultured for 21 days in the 359 
presence of BBGs and 45S5 bioglass®. In the images it is possible to observe the 360 
deposition of minerals over the dense layer of cells, when they were cultured in the 361 
presence of BBG-Mg, -Sr and 45S5 bioglass® (Figure 7a, 7c and 7d). The presence of 362 
these glass compositions in the culture medium promoted a mineralization typical to 363 
occur while BM-MSCs differentiate into osteoblasts. (38) This mineralization is in 364 
agreement with the alizarin red data where the mineral deposits were more evident in the 365 
cells cultured in the presence of BBG-Mg, -Sr and 45S5 bioglass® (Figure 6a, 6c and 6d). 366 
In these culture conditions, it is observed in the SEM/EDS images calcium phosphate 367 
deposits over the dense cellular layer. Once more, higher concentrations of BBG-Sr and 368 
45S5 bioglass® under basal culture conditions promoted the deposition of a higher 369 
amounts of calcium phosphate structures, suggesting that BBG-Sr and 45S5 bioglass® 370 
(Figure 7c and 7d basal for a concentration of 50 mg/ml) are capable of inducing ECM 371 
mineralization by themselves, which could be beneficial for bone regeneration. (39) 372 
3.2.4 Protein expression (OP and OC) 373 
Complementary to the reported biological data, the differentiation level of BM-MSC, 374 
cultured in the presence (20 and 50 mg/ml) and absence of BBG-Mg, -Ca, -Sr and 45S5 375 
bioglass® (either in basal or osteogenic media) was assessed by the quantification of the 376 
expression level of two major bone-specific proteins, i.e. OP and OC. The relative 377 
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expression of these proteins was normalized in relation to the number of cells, i.e. amount 378 
of dsDNA. It is well known that osteoblasts are differentiated cells that mineralize the 379 
bone matrix. OP is a phosphoprotein synthesized by bone forming cells, which present 380 
calcium-binding domains and is responsible for cell attachment, proliferation, and ECM 381 
mineralization. (40) In the case of OC, it is a bone-specific glycoprotein capable of 382 
binding to calcium, which promotes ECM calcification. (40) Not surprisingly, the OP and 383 
OC quantification data (Figure 8 and Figure 9) showed a significantly higher protein 384 
expression when BM-MCSs were cultured under osteogenic media rather than basal 385 
media. (41) In the case of OP, as expected, a delay in the protein synthesis is observed 386 
(Figure 8). At day 7 there was no significant difference of OP expression in relation to 387 
the control (absence of glass particles and cell culture in basal medium). However, at day 388 
14 there is a high expression peak by BM-MSCs cultured in osteogenic medium (in the 389 
presence of BBG-Mg, -Sr and 45S5 bioglass®), which determines the decay of the matrix 390 
deposition phase and the beginning of the mineralization phase. Moreover, BBG-Sr and 391 
45S5 bioglass® continue to induce a significant overexpression of OP over time (e.g. at 392 
day 21), supporting the mineralization demonstrated by ALP and alizarin red analysis 393 
(Figure 5 and 6, respectively). In the OC case there was a high protein expression up to 394 
day 14, indicating bone ECM maturation (Figure 9). (42) At day 7 there is a significant 395 
difference in OP expression in relation to the control (cell culture in basal medium and in 396 
the absence of glass particles). After day 7 there was a reduction of OC expression, 397 
consistent with matrix mineralization. Noteworthy is the observation that BBG-Sr under 398 
basal medium induced the BM-MSCs to exhibit a peak of OC expression at day 14. This 399 
data suggested that the BBG-Sr glass particles (at a concentration of 50 mg/ml) induced 400 
the OC protein expression, which is in agreement with the ALP and alizarin red data. 401 
Also, BBG-Sr and 45S5 bioglass® prolonged the OC overexpression over the 21 days of 402 
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culture. In addition, the 45S5 bioglass® promoted a high deposition of OC at day 21 403 
(Figure 4h) compared with high BM-MSCs density in the case of BBG-Sr (Figure 4f). 404 
However, it is important consider that in the case of the cultures in the presence of 45S5 405 
bioglass® a very low BM-MSCs cell density was observed, which might be related with 406 
the cytotoxicity of 45S5 bioglass®. (43) Therefore, and overall, our data suggests that the 407 
BBG-Sr glass particles are able to induce the BM-MSCs to express higher levels of OP 408 
and OC, while maintaining the BM-MSCs cell density. 409 
 410 
Figure 8. OP protein content of BM-MSCs cultured either with basal or osteogenic media 411 
in the presence of different concentrations (20 and 50 mg/ml) of BBG-Mg (a), BBG-Ca 412 
(b) and BBG-Sr (c). The 45S5 bioglass® (d) was used as control. Results are expressed as 413 
mean ± standard deviation with n = 3 for each bar. The data was analyzed by non-414 
parametric statistics: Kruskal-Wallis test (p<0.0001), followed by a Dunn’s Multiple 415 
Comparison test. *** p<0.001; ** p<0.01; * p<0.05 in respect to the control, i.e. BM-MSCs 416 
culture in basal media for the respective day of culture (i.e. 7, 14 and 21 days). 417 
 418 
 419 
Figure 9. OC protein content of BM-MSCs cultured either with basal or osteogenic media 420 
in the presence of different concentrations (20 and 50 mg/ml) of BBG-Mg (a), BBG-Ca 421 
(b) and BBG-Sr (c). The 45S5 bioglass® (d) was used as control. Results are expressed as 422 
mean ± standard deviation with n = 3 for each bar. The data was analyzed by non-423 
parametric statistics: Kruskal-Wallis test (p<0.0001), followed by a Dunn’s Multiple 424 
Comparison test. *** p<0.001; ** p<0.01; * p<0.05 in respect to the control, i.e. BM-MSCs 425 
culture in basal media for the respective day of culture (i.e. 7, 14 and 21 days). 426 
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Hence, combining the obtained biological data, i.e. viability, proliferation, mineralization 428 
and protein expression analysis (ALP, OC and OP), we were able to identify the BBG-429 
Mg, -Sr (at concentrations of 20 to 50 mg/ml) as relevant promoters of the osteogenic 430 
differentiation of BM-MSCs. Several authors reported that Mg2+ ions significantly 431 
enhanced osteoblast adhesion by the altering cell-matrix interactions, which modulate the 432 
function of integrins related with cell differentiation. (19, 44) Our results suggest that 433 
BBG-Mg also promoted BM-MSCs differentiation, which might be related with the 434 
presence of Mg2+ in the culture medium. Remarkably, BBG-Sr (at a concentration of 50 435 
mg/ml and 21 days of culture) presented the capacity to induce osteogenic response in 436 
BM-MSCs in the absence of osteogenic medium. Other authors reported Sr containing 437 
glasses to stimulate osteoblast metabolic activity, inhibiting osteoclast differentiation, as 438 
well as promoting the increment of ALP activity. (24) For instance, Hurtel-Lemaire et al. 439 
(45) have shown that Sr induces osteoclast apoptosis at concentrations higher than 9 mM. 440 
This is in accordance with our previous studies (29) that demonstrated a concentration of 441 
Sr in the culture media of about 20 mM after 3 days of culture. The ALP activity results 442 
showed the shift of BM-MSCs to a more differentiated state, while the alizarin red 443 
analysis demonstrated that the cells in the presence of BBG-Mg and BBG-Sr glass 444 
particles present intense and dispersed red spots in the cell culture, corresponding to the 445 
mineralization promoted by the BM-MSCs. Finally, Santocildes et al. (25) demonstrated 446 
that the dissolution of Sr-containing glasses stimulated the upregulation of genes 447 
associated with the process of osteogenic differentiation, such as Bglap (OC) and Spp1 448 
(OP). In agreement with this data, we also observed that BBGs-Mg an BBG-Sr might also 449 
influence the ECM maturation and mineralization, through the promotion of the OP and 450 
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OC protein overexpression, which suggests that these glass compositions may be 451 
effective in inducing and sustaining the osteoblastic phenotype. (46) 452 
4. Conclusion 453 
BBGs with different substituted divalent cations (Ca2+, Sr2+ or Mg2+) were successfully 454 
synthesized by melt quenching. In vitro studies demonstrated that the studied BBGs 455 
exhibit the capability to improve the osteogenic differentiation of BM-MSCs with no 456 
deleterious effects over cell viability and proliferation. Specially, BBG-Mg and BBG-Sr 457 
(at 20 and 50 mg/ml) provided favorable conditions for BM-MSCs to differentiate to 458 
osteoblast-like cells and induce the formation of a high amount of mineralized nodules. 459 
The phenotypic expression of two major bone-specific proteins, namely, OP and OC 460 
confirmed the osteogenic potential of the BBGs. 461 
The findings that the BBGs are able to promote in vitro cell differentiation into an 462 
osteogenic lineage, support their potential application in regenerative medicine. Based on 463 
these promising results we propose the incorporation of these BBGs into biomaterials for 464 
bone regeneration. The proposed BBGs are also relevant candidates for further in vivo 465 
evaluation. 466 
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